Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections

Expert Opinion on Drug Metabolism and Toxicology

Volumn 8, Issue 6, 2012, Pages 759-765

  Livermore, Joanne ^a   Hope, William ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Aspergillus; Itraconazole; Pharmacodynamics; Pharmacokinetics; Resistance; Triazole

Indexed keywords

CASPOFUNGIN; ISAVUCONAZOLE; ISAVUCONAZONIUM; KETOCONAZOLE; RIFAMPICIN; TACROLIMUS; VORICONAZOLE; WARFARIN;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; AREA UNDER THE CURVE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CANDIDA KRUSEI; CANDIDA TROPICALIS; CANDIDEMIA; CANDIDIASIS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; ELECTROCARDIOGRAM; HEADACHE; HUMAN; INVASIVE CANDIDIASIS; LIVER DYSFUNCTION; LIVER TOXICITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; REVIEW; RHINITIS; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; SYSTEMIC MYCOSIS; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIFUNGAL AGENTS; CANDIDIASIS, INVASIVE; DRUG INTERACTIONS; DRUG RESISTANCE, FUNGAL; HUMANS; INVASIVE PULMONARY ASPERGILLOSIS; NITRILES; PYRIDINES; TREATMENT OUTCOME; TRIAZOLES;

ASPERGILLUS;

EID: 84862062156     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2012.683859     Document Type: Review

References (19)

1. Denning DW, Hope WW. Therapy for fungal diseases: opportunities and priorities. Trends Microbiol.2010;18(5):195-204
2. Available from: WWW.CLINICALTRIALS.GOV
3. Chowdhary A, Kathuria S, Randhawa , et al. Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. J Antimicrob Chemother 2012;67(2):362-6
4. Howard SJ, Cerar D, Anderson MJ, et al. Frequency and evolution of azole resistance in aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 2009;15:1068-76
5. Schmitt-Hoffmann A, Roos B, Heep M, et al. Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug,BAL8557, in healthy volunteers.Antimicrob Agents Chemother 2006;50:279-85 (Pubitemid 43042933)
6. Schmitt-Hoffmann A, Roos B, Maares J, et al. Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother 2006;50:286-93 (Pubitemid 43042934)
7. Schmitt-Hoffmann A, Roos B, Spickermann J, et al. Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557. Antimicrob Agents Chemother 2009;53:4885-90
8. Warn PA, Sharp A, Parmar A, et al. Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. Antimicrob Agents Chemother 2009;53:3453-61
9. Hope WW. Population pharmacokinetics of voriconazole in adults. Antimicrob Agents Chemother 2012;56(1):526-31
10. Schmitt-Hoffmann A, Roos Bspickerman J. No relevant food effect in man on isavuconazole oral pharmacokinetics preliminary data. 48th International Conference on Antimicrobial Agents and Chemotherapy; Washington, D.C; 2008
11. Schmitt-Hoffmann A, Roos Bsauer J. Effect of rifampicin on the pharmacokinetics of BAL4815 at steady state after multiple oral daily doses of BAL8557 (WSA) and rifampicin. 16th Congress of the International Society of Human and Animal Mycology; Paris, France; 2006
12. Schmitt-Hoffmann A, Roos Bsauer J. Effect of ketoconazole on the pharmacokinetics of BAL4815 at steady state after multiple oral daily doses of BAL8557 (WSA) and ketoconazole. 16th Congress of the International Society of Human and Animal Mycology; Paris, France; 2006
13. Schmitt-Hoffmann A, Roos Bsauer J. Effect of BAL8557, a water-soluble azole pro-drug (WSA) on the pharmacokinetics of S- and R- warfarin. 16th Congress of the International Society of Human and Animal Mycology; Paris, France; 2006
14. Schmitt-Hoffmann A, Roos Bsauer J. Effect of BAL8557, a water-soluble azole pro-drug (WSA) on the pharmacokinetics of tacrolimus. 16th Congress of the International Society of Human and Animal Mycology; Paris, France; 2006
15. Schmitt-Hoffmann A, Roos Bsauer J. Effect of BAL8557, a water-soluble azole pro-drug (WSA) on the pharmacokinetics of cicosporin. 16th Congress of the International Society of Human and Animal Mycology; Paris, France; 2006
16. Thompson GR III, Wiederhold NP. Isavuconazole: a comprehensive review of spectrum of activity of a new triazole. Mycopathologia 2010;170:291-313
17. Majithiya J, Sharp A, Parmar A, et al. Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei. J Antimicrob Chemother 2009;63:161-6
18. Warn PA, Sharp A, Mosquera J, et al. Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus. J Antimicrob Chemother 2006;58:1198-207 (Pubitemid 44884139)
19. Viljoen J. Efficacy, safety and tolerability of three different dosing regimens of BAL8557 vs. fluconazole in a double-blind, randomised, multicentre trial for the treatment of esophageal candidiasis in immunocompromised adults. 45th International Conference on Antimicrobial Agents and Chemotherapy; Washingon, D.C; 2005